Ongoing or excluded trials recently added
03/03/2010 -
(TRA 2 degrees P)-TIMI 50
-
SCH 530348 2.5 mg daily versus placebo
cardiovascular prevention - antiplatelets drug - all type of patients
cardiovascular prevention - antiplatelets drug - secondary prevention in patients with intermittent claudication
cardiovascular prevention - antiplatelets drug - secondary prevention in patients with CAD
29/01/2010 -
CABANA
-
left atrial catheter ablation versus current state-of-the-art therapy with either rate control or rhythm control drugs
atrial fibrillation - catheter ablation - all type of patients
16/01/2010 -
B0661004
-
Apixaban 2.5 or 5 mg twice daily versus placebo
acute coronary syndrome - antithrombotics - all type of patient
acute coronary syndrome - anticoagulant - All ACS (including AMI)
acute coronary syndrome - direct factor Xa inhibitors - all type of patients
acute coronary syndrome - antithrombotics - patients with a recent ACS
16/01/2010 -
APPRAISE 2 (CV185-068)
-
apixaban 5mg twice daily versus placebo
acute coronary syndrome - antithrombotics - all type of patient
acute coronary syndrome - anticoagulant - All ACS (including AMI)
acute coronary syndrome - direct factor Xa inhibitors - all type of patients
acute coronary syndrome - antithrombotics - patients with a recent ACS
16/01/2010 -
ARISTOTLE (CV185-030)
-
apixaban 5mg twice daily
versus warfarin adjusted for an INR between 2 and 3
atrial fibrillation - antithrombotics - primary prevention of thromboembolic events
atrial fibrillation - direct factor Xa inhibitors - all type of patients
atrial fibrillation - new oral anticoagulant - all type of patients
16/01/2010 -
AVERROES (CV185-048)
-
apixaban 5 mg (or 2.5 mg) twice daily versus aspirin 81-324 md daily
atrial fibrillation - antithrombotics - primary prevention of thromboembolic events
atrial fibrillation - direct factor Xa inhibitors - all type of patients
atrial fibrillation - new oral anticoagulant - all type of patients
16/01/2010 -
B0661003
-
apixaban 5 or 2.5 mg twice daily versus warfarin
atrial fibrillation - antithrombotics - primary prevention of thromboembolic events
atrial fibrillation - direct factor Xa inhibitors - all type of patients
atrial fibrillation - new oral anticoagulant - all type of patients
14/01/2010 -
CV185-036
-
apixaban 2.5mg twice daily, 30 days versus enoxaparin 40mg once daily 6-14 days
DVT prophylaxis - anticoagulant - orthopedic surgery
DVT prophylaxis - direct factor Xa inhibitors - all type of patients
DVT prophylaxis - new oral anticoagulant - all type of patients
18/12/2009 -
INNOVATE
-
versus
acute myocardial infarction - antiplatelets drug - all type of patients
23/10/2009 -
NCT00494871
-
rivaroxaban 10mg daily versus warfarin adjusted dose
atrial fibrillation - antithrombotics - primary prevention of thromboembolic events
atrial fibrillation - direct factor Xa inhibitors - all type of patients
atrial fibrillation - new oral anticoagulant - all type of patients
23/10/2009 -
Einstein-DVT Evaluation
-
Rivaroxaban versus Enoxaparin followed by VKA
venous thrombosis - antithrombotics - all type of patients
venous thrombosis - direct factor Xa inhibitors - all type of patients
23/10/2009 -
Einstein-PE Evaluation
-
versus
venous thrombosis - antithrombotics - all type of patients
venous thrombosis - direct factor Xa inhibitors - all type of patients
23/09/2009 -
MARVEL
-
autologous myoblasts by intramyocardial injection at doses containing 400 or 800 million cells versus sham procedure
acute myocardial infarction - cell-based therapies - PCI
21/09/2009 -
ESTATE
-
atorvastatin given immediately before PCI versus
percutaneous coronary intervention - statin - all type of patients
18/09/2009 -
DAPT
-
additional 18 months of thienopyridine treatment versus placebo
stent - antithrombotics - all type of patients
percutaneous coronary intervention - antithrombotics - PCI with stent placement
18/09/2009 -
BRAVE-4
-
Prasugrel + Bivalirudin versus Clopidogrel + Heparin
percutaneous coronary intervention - antithrombotics - all type of patients
13/09/2009 -
NCT00975234
-
Intra-lesion injection of autologous skeletal myoblasts versus placebo
acute myocardial infarction - cell-based therapies - PCI
26/08/2009 -
CURRENT OASIS 7 (clopidogrel)
-
versus
acute coronary syndrome - antithrombotics - all type of patient
acute coronary syndrome - antiplatelets drug - ACS (excluding AMI)
acute coronary syndrome - antiplatelets drug - all type of patients
26/08/2009 -
CURRENT - OASIS 7 (ASA)
-
versus
acute coronary syndrome - antithrombotics - all type of patient
acute coronary syndrome - antiplatelets drug - ACS (excluding AMI)
acute coronary syndrome - antiplatelets drug - all type of patients
21/07/2009 -
PLAATO
-
versus
atrial fibrillation - embolic protection - all type of patients
20/07/2009 -
ENGAGE-AF TIMI 48
-
edoxaban 30 or 60mg once daily versus warfarin (INR 2-3)
atrial fibrillation - antithrombotics - primary prevention of thromboembolic events
atrial fibrillation - direct factor Xa inhibitors - all type of patients
atrial fibrillation - new oral anticoagulant - all type of patients
20/07/2009 -
EmbraceAC
-
tecarfarin versus warfarin
atrial fibrillation - antithrombotics - primary prevention of thromboembolic events
14/07/2009 -
TRANSFER-AMI
-
pharmacoinvasive strategy (transfer for PCI within six hours of fibrinolysis) versus standard treatment after fibrinolysis (rescue PCI for failed reperfusion, with elective PCI encouraged for successfully reperfused patients after 24 hours)
acute myocardial infarction - myocardial revascularization - all type of patients
|